Treatment and Management of Lung Large Cell Neuroendocrine Carcinoma (LCNEC) - Episode 9

The Role of DLL3 in LCNEC of the Lung

,

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

Current Time 0:00
Duration 2:17
Loaded: 0%
Stream Type LIVE
Remaining Time 2:17
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: Lung Large Cell Neuroendocrine Carcinoma: A Rare but Aggressive Disease Intro
EP. 2: An Overview of the Molecular Characterization of Lung LCNEC
EP. 3: The Pathological Diagnosis of Lung LCNEC
EP. 4: Biomarker Testing Strategies for Lung LCNEC
EP. 5: Biopsy Best Practices: Diagnosing Lung LCNEC
EP. 6: Lung LCNEC Diagnostic Challenges
EP. 7: A Multidisciplinary Approach to Managing Lung LCNEC
EP. 8: Lung LCNEC Disease Histology and Prognosis
Now Viewing
EP. 9: The Role of DLL3 in LCNEC of the Lung
EP. 10: Insights on the LANCE Pilot Study on Lung LCNEC
EP. 11: Novel Targeted Therapies for LCNEC of the Lung
EP. 12: Overview of Studies of BI 764532 for Lung LCNEC
EP. 13: Insights Into Ongoing Investigational Studies in Lung LCNEC
EP. 14: Potential Next-Generation Therapies for Lung LCNEC
EP. 15: Unmet Needs in LCNEC
  • Given the limited therapeutic options for patients with lung LCNEC, what is your typical treatment approach?
    • What patient-specific factors do you consider to guide your first-line treatment selection?
  • Please share your thoughts on the ASCO 2024 retrospective studies examining first-line systemic treatment outcomes: 1. (Nassar et al, ASCO 2024); 2. (Matteson et al., ASCO 2024)
    • What are your key considerations for choosing a second-line treatment strategy?
    • How has the tarlatamab approval in SCLC(Ahn et al., NEJM 2023) impacted your treatment approach for patients with LCNEC?
x